Deprescribing proton pump inhibitors Evidence-based clinical practice guideline

被引:3
|
作者
Farrell, Barbara [1 ,2 ,3 ]
Pottie, Kevin [4 ,5 ,6 ]
Thompson, Wade [5 ]
Boghossian, Taline [7 ]
Pizzola, Lisa [6 ]
Rashid, Farah Joy [7 ]
Rojas-Fernandez, Carlos [8 ,9 ]
Walsh, Kate [10 ]
Welch, Vivian [5 ,11 ]
Moayyedi, Paul [12 ]
机构
[1] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada
[2] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[3] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada
[4] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada
[5] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada
[6] Bruyere Res Inst, Ottawa, ON, Canada
[7] Ottawa Hosp, Dept Pharm, Ottawa, ON, Canada
[8] Univ Waterloo, Geriatr Pharmacotherapy, Schlegel UW Res Inst Ageing, Waterloo, ON, Canada
[9] Univ Waterloo, Sch Pharm, Waterloo, ON, Canada
[10] Toronto Cent Community Care Access Ctr, Toronto, ON, Canada
[11] Bruyere Res Inst, Methods Ctr, Ottawa, ON, Canada
[12] McMaster Univ, Div Gastroenterol, Hamilton, ON, Canada
关键词
GASTROESOPHAGEAL-REFLUX DISEASE; PANTOPRAZOLE; 20; MG; MAINTENANCE TREATMENT; LONG-TERM; ON-DEMAND; CONTROLLED TRIAL; PRIMARY-CARE; THERAPY; ESOPHAGITIS; MANAGEMENT;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To develop an evidence-based guideline to help clinicians make decisions about when and how to safely taper or stop proton pump inhibitors (PPIs); to focus on the highest level of evidence available and seek input from primary care professionals in the guideline development, review, and endorsement processes. Methods Five health professionals (1 family physician, 3 pharmacists, and 1 gastroenterologist) and 5 nonvoting members comprised the overall team; members disclosed conflicts of interest. The guideline process included the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach, with a detailed evidence review in in-person, telephone, and online meetings. Uniquely, the guideline development process included a systematic review of PPI deprescribing trials and examination of reviews of the harm of continued PPI use. Narrative syntheses of patient preferences and resource-implication literature informed recommendations. The team refined guideline content and recommendation wording through consensus and synthesized clinical considerations to address common front-line clinician questions. The draft guideline was distributed to clinicians and then to health care professional associations for review and revisions made at each stage. A decision-support algorithm was developed in conjunction with the guideline. Recommendations This guideline recommends deprescribing PPIs (reducing dose, stopping, or using "on-demand" dosing) in adults who have completed a minimum of 4 weeks of PPI treatment for heartburn or mild to moderate gastroesophageal reflux disease or esophagitis, and whose symptoms are resolved. The recommendations do not apply to those who have or have had Barrett esophagus, severe esophagitis grade C or D, or documented history of bleeding gastrointestinal ulcers. Conclusion This guideline provides practical recommendations for making decisions about when and how to reduce the dose of or stop PPIs. Recommendations are meant to assist with, not dictate, decision making in conjunction with patients.
引用
收藏
页码:354 / 364
页数:11
相关论文
共 50 条
  • [1] Development of an evidence-based clinical practice guideline for deprescribing cholinesterase inhibitors and memantine
    Reeve, E.
    Farrell, B.
    Rockwood, K.
    Hilmer, S.
    [J]. AUSTRALASIAN JOURNAL ON AGEING, 2018, 37 : 41 - 41
  • [2] Deprescribing benzodiazepine receptor agonists Evidence-based clinical practice guideline
    Pottie, Kevin
    Thompson, Wade
    Davies, Simon
    Grenier, Jean
    Sadowski, Cheryl A.
    Welch, Vivian
    Holbrook, Anne
    Boyd, Cynthia
    Swenson, Robert
    Farrell, Andy Ma Barbara
    [J]. CANADIAN FAMILY PHYSICIAN, 2018, 64 (05) : 339 - 351
  • [3] Evidence-based deprescribing of proton pump inhibitors in long-term care
    Sluggett, Janet K.
    Hendrix, Ivanka
    Bell, J. Simon
    [J]. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2018, 14 (02): : 124 - 126
  • [4] Deprescribing antihyperglycemic agents in older persons Evidence-based clinical practice guideline
    Farrell, Barbara
    Black, Cody
    Thompson, Wade
    McCarthy, Lisa
    Rojas-Fernandez, Carlos
    Lochnan, Heather
    Shamji, Salima
    Upshur, Ross
    Bouchard, Manon
    Welch, Vivian
    [J]. CANADIAN FAMILY PHYSICIAN, 2017, 63 (11) : 832 - 843
  • [5] Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia Evidence-based clinical practice guideline
    Bjerre, Lise M.
    Farrell, Barbara
    Hogel, Matthew
    Graham, Lyla
    Lemay, Genevieve
    McCarthy, Lisa
    Raman-Wilms, Lalitha
    Rojas-Fernandez, Carlos
    Sinha, Samir
    Thompson, Wade
    Welch, Vivian
    Wiens, Andrew
    [J]. CANADIAN FAMILY PHYSICIAN, 2018, 64 (01) : 17 - 27
  • [6] Deprescribing Proton Pump Inhibitors
    Zed, Peter J.
    [J]. CANADIAN JOURNAL OF HOSPITAL PHARMACY, 2018, 71 (05): : 291 - 292
  • [7] Deprescribing proton pump inhibitors
    Turner, Justin P.
    Thompson, Wade
    Reeve, Emily
    Bell, J. Simon
    [J]. AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2022, 51 (11) : 845 - 848
  • [8] Deprescribing Proton Pump Inhibitors: Updated Clinical Guidelines
    Gaulke, Carolyn
    [J]. JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2024, 20 (09):
  • [9] Deprescribing proton pump inhibitors
    Teh, Kim Jun Kevin
    Puar, Hai Kiat Troy
    How, Choon How
    Tan, Teck Kiang Malcolm
    [J]. SINGAPORE MEDICAL JOURNAL, 2023, 64 (08) : 503 - 507
  • [10] Deprescribing Proton Pump Inhibitors
    Kurlander, Jacob E.
    Gonzalez, Juan J.
    Saini, Sameer D.
    [J]. JAMA INTERNAL MEDICINE, 2020, 180 (12) : 1711 - 1712